Cannabis Law Report
OCTOBER 2, 2021
The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. Founded in 2014, MAPS PBC is a Public Benefit Corporation that prioritizes public benefit over profit. Competitive benefit package includes: Paid Time Off (PTO).
Cannabis Law Report
AUGUST 23, 2021
At the end of the programme, Evotec will provide the Company with a submission-ready regulatory document which will be used for submissions to regulatory agencies, as well as drug-batch approved and ready for First Time in Human clinical trials. The planning phase has been completed and “wet-work” initiated as per proposed timelines.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JULY 28, 2021
Founded in 2014, MAPS PBC is a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS) a 501(c)(3) nonprofit. 2-3 years of relevant experience in clinical trials, research methods, or statistical design and analysis. Experience working for a clinical study Sponsor.
Weedistry
MARCH 11, 2019
The packaging, with a baronial crest and gold accents, would look at home in a fashionable department store. A lot of my friends have been getting their products from more ‘luxury’ cannabis suppliers who are focusing on packaging and branding,” he said. That celebrities use the products adds additional cachet.
Cannabis Law Report
JUNE 4, 2021
We believe there is a benefit to Delta-8 but there should be labeling or warnings on packages so that consumers are informed of potential minor intoxication effects. As a graduate student, he received the IPMI Richard Rubin Memorial Scholarship in 2014 for his research in precious metals.
Cannabis Law Report
AUGUST 25, 2022
United States Sentencing Commission, which establishes and advises Congress on federal sentencing guidelines, reaches first quorum in 3 years and a full slate for first time since 2014. MAPS is sponsoring the most advanced psychedelic therapy research in the world: Phase 3 clinical trials of MDMA-assisted therapy for PTSD.
Cannabis Law Report
JULY 12, 2019
Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. References. Checklin1,2, Richard L.
Expert insights. Personalized for you.
52 
Let's personalize your content